Yang Mingzheng, Kan Lin, Wu Lianye, Zhu Yingchun, Wang Qing
Department of Nephrology, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai 201700, P.R. China.
Department of Clinical Laboratory, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai 201700, P.R. China.
Exp Ther Med. 2019 Mar;17(3):2071-2076. doi: 10.3892/etm.2019.7181. Epub 2019 Jan 17.
The present study observed the effect of baicalin on blood glucose and renal function in patients with diabetic nephropathy and explored its mechanism of action. A total of 95 patients diagnosed with diabetic nephropathy by clinical and laboratory examinations were selected and randomly divided into a control and treatment group. The control group included 45 patients who were treated with routine symptomatic treatment. The remaining 50 patients in the treatment group received baicalin, in addition to routine symptomatic treatment. The treatment course was 6 months. Following this, the changes of indicators such as fasting plasma glucose (FPG), glycosylated hemoglobin (HBA1c), aldose reductase (AR) activity, 24-h urinary microalbumin, urinary β2-microglobulin (β2-MG) and urinary albumin excretion rate (UAER) were compared before and after treatment; at the same time, the variations of indexes, including superoxide dismutase (SOD), glutathione peroxidase (GSH-px), nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB), transforming growth factor-β1 (TGF-β1) and vascular endothelial growth factor (VEGF) were detected. Compared with those in the control group, baicalin had little effect on the treatment group's FPG and HBA1c, but it clearly reduced the AR activity and the difference was significant (P<0.05). Baicalin visibly decreased the 24-h urinary microalbumin, urinary β2-MG and UAER (P<0.05) and had notable effect on improving renal function. Following treatment, compared with those in the control group, baicalin distinctly increased the levels of SOD and GSH-px (P<0.05) and decreased the content of NF-κB and VEGF (P<0.05), however, its impact on the expression of TGF-β1 was not statistically significant (P>0.05). The results showed that baicalin may improve the renal function in patients with diabetic nephropathy and delay the progression of diabetic nephropathy through various ways, including anti-inflammation and anti-oxidation.
本研究观察了黄芩苷对糖尿病肾病患者血糖及肾功能的影响，并探讨其作用机制。通过临床及实验室检查确诊为糖尿病肾病的95例患者被选取并随机分为对照组和治疗组。对照组45例患者接受常规对症治疗。治疗组其余50例患者在常规对症治疗基础上给予黄芩苷治疗。疗程为6个月。此后，比较治疗前后空腹血糖（FPG）、糖化血红蛋白（HBA1c）、醛糖还原酶（AR）活性、24小时尿微量白蛋白、尿β2-微球蛋白（β2-MG）及尿白蛋白排泄率（UAER）等指标的变化；同时，检测超氧化物歧化酶（SOD）、谷胱甘肽过氧化物酶（GSH-px）、活化B细胞核因子κ轻链增强子（NF-κB）、转化生长因子-β1（TGF-β1）及血管内皮生长因子（VEGF）等指标的变化。与对照组相比，黄芩苷对治疗组FPG和HBA1c影响不大，但明显降低了AR活性，差异有统计学意义（P<0.05）。黄芩苷明显降低了24小时尿微量白蛋白、尿β2-MG及UAER（P<0.05），对改善肾功能有显著作用。治疗后，与对照组相比，黄芩苷明显提高了SOD和GSH-px水平（P<0.05），降低了NF-κB和VEGF含量（P<0.05），但其对TGF-β1表达的影响无统计学意义（P>0.05）。结果表明，黄芩苷可能通过抗炎、抗氧化等多种途径改善糖尿病肾病患者的肾功能，延缓糖尿病肾病的进展。
